RT Journal Article
SR Electronic
T1 Endocrine Comorbidities in Patients with Psoriatic Arthritis: A Population-based Case-controlled Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 786
OP 790
DO 10.3899/jrheum.161274
VO 44
IS 6
A1 Amir Haddad
A1 Ron Ilan Ashkenazi
A1 Haim Bitterman
A1 Ilan Feldhamer
A1 Sari Greenberg-Dotan
A1 Idit Lavi
A1 Erez Batat
A1 Irina Bergman
A1 Arnon Dov Cohen
A1 Devy Zisman
YR 2017
UL http://www.jrheum.org/content/44/6/786.abstract
AB Objective. To investigate endocrine comorbidities in patients with psoriatic arthritis (PsA).Methods. A retrospective, cross-sectional study was performed with the database of Clalit Health Services, the largest healthcare provider in Israel, between 2002 and 2014. Patients with PsA were identified and matched by age and sex to healthy controls. The following morbidities were analyzed: hypo/hyperthyroidism, hypo/hyperparathyroidism, hyperprolactinemia, Cushing disease, Addison disease, diabetes insipidus, diabetes mellitus (DM), pituitary adenoma, acromegaly, and osteoporosis. Descriptive statistics were applied. The associations between PsA and endocrine comorbidities were analyzed by univariable and multivariable analysis.Results. The study included 3161 patients with PsA, 53.4% women, mean age 58.4 ± 15.4 years, and 31,610 controls. Comparative analyses yielded higher proportion of hypothyroidism (12.7% vs 8.6%, p < 0.0001), Cushing disease (0.3% vs 0.1%, p < 0.0001), osteoporosis (13.2% vs 9.1%, p < 0.0001), and DM (27.9% vs 20.7%, p < 0.0001) in the PsA group compared with the control group. In the multivariable regression analysis, the following diseases were more frequent in the PsA group: hypothyroidism (OR 1.61, 95% CI 1.47–1.81), DM (OR 1.35, 95% CI 1.18–1.42), Cushing disease (OR 3.96, 95% CI 1.67–9.43), and osteoporosis (OR 1.56, 95% CI 1.37–1.78).Conclusion. PsA is associated with a high frequency of hypothyroidism, osteoporosis, DM, and Cushing disease. Awareness of these comorbidities may help physicians provide the optimal medical care to patients with PsA.